Subscribe or Manage Preferences

ASH 2015 - Leukemia

The ongoing randomized ENESTPath phase 3 trial evaluated the optimal duration of nilotinib therapy needed to achieve and maintain treatment-free remission upon treatment discontinuation in patients with chronic-phase chronic myeloid leukemia (CP-CML). The results of the first 300 patients treated with nilotinib for ≥1 years were reported.
Subset analysis results of patients who had undergone allogeneic hematopoietic stem-cell transplantation (HSCT) prior to blinatumomab therapy in the single-arm, phase 2 study of patients with Philadelphia chromosome–negative relapsed/refractory acute lymphoblastic leukemia (ALL) were reported.
The 24-month phase 3b ENEST–Extending Molecular Responses (ENESTxtnd) study evaluated the kinetics of molecular response to nilotinib 300 mg twice daily and novel dose-optimization strategies in de novo patients with chronic-phase chronic myeloid leukemia (CML-CP); the results of the study were reported by Hughes and colleagues.
Researchers reported the randomized phase 3 CALGB 10603/RATIFY trial that evaluated the benefit of the midostaurin addition to induction and consolidation therapy followed by maintenance therapy in improving efficacy and survival outcomes compared with standard chemotherapy in younger adults with activating FLT3 mutations.
Results of the BMT CTN 0901 randomized phase 3 trial that compared outcomes by conditioning intensity, reduced-intensity conditioning versus myeloablative conditioning, in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) were reported.
Joseph M. Connors, MD, gives examples of how personalized medicine has influenced how he treats patients with lymphoid malignancies and how his patients have positively responded to these treatments.
Results of the multicenter phase 2 ALCANTARA trial that evaluated the efficacy and tolerability of blinatumomab immunotherapy in poor prognosis patients with relapsed/refractory Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) who progressed after or were intolerant to second- or later-generation tyrosine kinase inhibitors were reported.
Results of the long-term 18-month follow-up analysis of a multicenter phase 2 study that evaluated single-agent blinatumomab treatment in patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL) were reported.
The long-term safety and antitumor activity of 19-28z CAR T-cells in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) from a phase 1 clinical trial were reported. The roles of posttreatment minimal residual disease negativity and allogeneic hematopoietic stem-cell transplantation prior to or following CAR T-cell infusion on safety and clinical outcome were also reported.
Results of the generic and cancer-specific quality-of-life assessment conducted in the SPIRIT2 (STI571 Prospective International Randomised Trial 2) trial that compared the safety and efficacy of first-line dasatinib (100 mg once daily) and imatinib (400 mg once daily) as first-line therapy in patients with chronic myeloid leukemia (CML) were reported.
Page 1 of 3
Results 1 - 10 of 23
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology